Novartis reports positive results for intrathecal Zolgensma
Novartis (NVS) said a Phase 3 study of an intrathecal formulation of its gene therapy Zolgensma met its primary endpoint in ...
Monthly Prescribing Reference1d
Gene Therapy Improves Motor Function in Spinal Muscular Atrophy Type 2
The phase 3 STEER study enrolled 127 treatment-naïve patients aged 2 to less than 18 years with SMA type 2 who were able to sit but had never walked independently.
Hosted on MSN20h
Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint
Novartis has reported positive topline outcomes from the Phase III STEER trial of an investigational gene therapy, ...
Novartis2d
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onasemnogene abeparvovec (OAV101 IT) OAV101 IT ...
Zacks.com on MSN16h
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
Novartis NVS announced positive top-line results from the late-stage STEER study on experimental candidate intrathecal ...
precisionmedicineonline19h
Novartis Reports Positive Data for Zolgensma in Young Adult Spinal Muscular Atrophy Population
The firm said it plans to share data with regulatory agencies from the Phase III STEER trial after it met its primary endpoint.
Bloomberg L.P.5d
SMA Solar Technology AG
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
Finbold | Finance in Bold5d
Uniswap And Aptos Face Huge Volatility In Recent Bearish Wave As Investors Hedge Their Holdings With FX Guys
In addition, analysts have reported that UNI could be in a bearish wave and has a huge resistance at $16.9. Yet, UNI could soon be in upward momentum as it has broken from consolidation phasing and is ...